Safety and Tolerability of Metastasis-Directed Radiation Therapy in the Era of Evolving Systemic, Immune, and Targeted Therapies

Guimond, Elizabeth; Tsai, Dr Chiaojung Jillian; Hosni, Ali; O’Kane, Grainne M.; Yang, Dr Jonathan; Barry, Aisling

doi:10.1016/j.adro.2022.101022

Cited by 14 publications

(10 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BRAF is among the most mutated genes, being identified approximately in 8% of human cancers, 8 and has been subject to multiple studies on targeted therapies. However, limited data are available regarding the safety and side effects of concurrent administration of BRAFi and RT 13 . When BRAFi was used in combination with RT, dermatitis was the most commonly reported side effect 4,5,13 .…”

Section: Discussionmentioning

confidence: 99%

“…13 When BRAFi was used in combination with RT, dermatitis was the most commonly reported side effect. 4,5,13 A large cohort of melanoma patients treated with RT and concomitant BRAFi showed a 36% increase in acute radiodermatitis ≥ Grade 2. 12 It is possible that BRAFi has radiosensitizing effects on normal keratinocytes as well.…”

Section: Discussionmentioning

confidence: 99%

“…However, limited data are available regarding the safety and side effects of concurrent administration of BRAFi and RT 13 . When BRAFi was used in combination with RT, dermatitis was the most commonly reported side effect 4,5,13 . A large cohort of melanoma patients treated with RT and concomitant BRAFi showed a 36% increase in acute radiodermatitis ≥Grade 2 12 .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A Rare Case of BRAF-mutated Metastatic Pleomorphic Xanthoastrocytoma Patient who Developed Radiodermatitis After Receiving Anti-BRAF Treatment

Atahan,

Arslantas,

Ersen Danyeli

et al. 2023

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Pleomorphic xanthoastrocytoma (PXA) is a rare type of grade 2 or 3 brain tumor that usually occurs in children and young adults. The standard treatment for PXA is maximally safe resection, usually with adjuvant radiation therapy, for high-grade tumors. BRAF V600E mutation is one of the most common molecular alterations in these tumors, with nearly 70% of cases carrying this mutation. Although BRAF inhibitors have shown promise in treating progressive or refractory disease, their use has been associated with various adverse effects, including radiodermatitis, which is a relatively common complication. This paper presents a case of a 16-year-old male patient with BRAF-mutated metastatic PXA, who developed mild radiodermatitis after receiving BRAF inhibitors with concurrent radiation therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Rare Case of BRAF-mutated Metastatic Pleomorphic Xanthoastrocytoma Patient who Developed Radiodermatitis After Receiving Anti-BRAF Treatment

Atahan,

Arslantas,

Ersen Danyeli

et al. 2023

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

show abstract

“…In contrast, the radiosenzitizing effect of targeted therapies can cause severe side effects, if applied concomitantly with radiotherapy, such as abscess in the brain, or severe, potentially fatal rectal fistula. According to international protocols we suspended targeted therapies 1 day before and after SRT/SRS which proved to be safe, considering that no serious adverse-events were observed ( 22 ). In our study the Kaplan-Meier method and log-rank statistics showed significance between the presence of brain metastases and progression-free survival; and near significance between the M stage and overall survival, and the LDH level was detected ( Figure 2 ).…”

Section: Discussionmentioning

confidence: 99%

The Role of Stereotactic Radiotherapy in the Management of Melanoma, A Retrospective Single Institute Preliminary Study of 30 Patients

Kispál¹,

Janvary²,

Balatoni³

et al. 2022

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Cutaneous melanoma is the third most common type of skin cancer in the world. The incidence of melanoma is increasing in most countries, however, mortality seems to be slowly decreasing. The treatment of advanced cutaneous melanoma changed radically since 2011. The new therapeutic modalities, such as immuno- and targeted therapies give a chance to successfully reach more prolonged progression-free survival (PFS) and overall survival (OS) in patients with metastatic melanoma. Despite the great therapeutic benefit, most patients eventually develop resistance to these therapies, and the disease will progress. In some cases oligoprogression develops. In those cases local therapy, such as stereotactic radiotherapy can make it possible to continue the previously applied effective medical treatment for the benefit of patients. In our study of a total of 30 patients—20 of them received pre-treatment with systemic medical therapy—received stereotactic radiotherapy using various systems, in the National Institute of Oncology, Hungary, Budapest. We managed to prolong the systemic therapy for 12.5 months median period with the assistance of CyberKnife technique. Therapy related adverse events were mostly tolerable with only 3% of Grade 3 toxicity. We concluded that stereotactic radiotherapy and stereotactic radiosurgery, are safe, and effective therapeutic modalities for regional tumor control in cases of oligoprogression.

show abstract

“…Jia et al [60] found a high rate of grade 3 or superior pneumonitis (54%), including a Common Terminology Criteria for Adverse Events (CTCAE) grade 5, when palliative RT was associated to osimertinib. Zhou et al [61] evaluated the safety of whole brain RT with or without EGFR TKIs. The combination of the treatments improves the ORR and 1-year survival rate.…”

Section: )mentioning

confidence: 99%

Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach

Di Pressa,

Perrone,

Benini

et al. 2024

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

Recently, the development of targeted therapy approaches such as those based on tyrosine kinase inhibitor (TKI) greatly improved the clinical outcomes of patients affected by oncogene addicted advanced non-small cell lung cancer (NSCLC). Similarly, the improvement of radiation therapy techniques has permitted to deliver high radiation doses to a limited number of metastatic target lesions (oligopersistent or oligoprogressive), with limited high-dose normal tissue exposure that leads to low severe toxicity rates. The aim of this narrative review was to provide an overview of the currently established definition of oligometastatic and oligoprogressive disease, to define first line and subsequent lines targeted therapies and the role of consolidative non-invasive local ablative treatments (LATs) in these settings. The potential benefit of local treatment (LT) such as radiotherapy (RT) or surgery might be represented by an overall reduction of switching to subsequent systemic treatments lowering the risk of further systemic dissemination. Further randomized clinical trials will clarify the role of LT and their correct timing in relation to systemic targeted therapies.

show abstract

Safety and Tolerability of Metastasis-Directed Radiation Therapy in the Era of Evolving Systemic, Immune, and Targeted Therapies

Cited by 14 publications

References 132 publications

A Rare Case of BRAF-mutated Metastatic Pleomorphic Xanthoastrocytoma Patient who Developed Radiodermatitis After Receiving Anti-BRAF Treatment

A Rare Case of BRAF-mutated Metastatic Pleomorphic Xanthoastrocytoma Patient who Developed Radiodermatitis After Receiving Anti-BRAF Treatment

The Role of Stereotactic Radiotherapy in the Management of Melanoma, A Retrospective Single Institute Preliminary Study of 30 Patients

Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach

Contact Info

Product

Resources

About